London – A dengue fever pill manufactured by Johnson & Johnson appeared to protect against a version of the virus in a few patients, in a tiny human challenge trial conducted in the United States. Before presenting the research at the American Society of Tropical Medicine and Hygiene Annual Meeting in Chicago, the company noted that there are presently no …
PENNSYLVANIA – The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO).1 The trial achieved all primary and secondary efficacy endpoints. A greater proportion of patients who received JNJ-2113 achieved …
London – Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma RARITAN, N.J., June 6, 2023 – The Janssen Pharmaceutical Companies of Johnson …
London (AFP) – A new study, published in the journal BMJ, was the first to compare thrombocytopenia rates between adenovirus and mRNA vaccines — such as Pfizer — across multiple countries. It has found that AstraZeneca’s Covid vaccine is linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab. Several countries …
London – If someone asked you what the most deadly animal in the world is, you might first think of lions or crocodiles. But—perhaps surprisingly—it’s the mosquito: These tiny insects are responsible for killing over 1 million people each year. Mosquitoes can spread serious diseases, including Zika, malaria, West Nile and dengue, the last of which the World Health Organization (WHO) named a top 10 …
London – Johnson & Johnson is deploying the full strength of its science, scale and expertise to help fight the pandemic as Covid-19 continues to affect people and communities across the world. J&J’s Janssen is using the same technology that it has used in the development of its Ebola vaccine and investigational HIV, RSV and Zika vaccine candidates, which involves using an inactivated common cold …
London – Championing global health equity, advancing environmental health and empowering its employees to be their best are just some of the ways Johnson & Johnson is working to help improve the well-being of people around the world. The company’s 2021 Health for Humanity Report reveals just how far it’s come toward these ambitious goals. Improving the trajectory of health …
TITUSVILLE – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives. Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted …
New York – Getting COVID-19 vaccines to people around the world. It’s hard to think of anything else right now, and it’s something that’s been top of mind at Johnson & Johnson since early last year, when the novel coronavirus was just beginning to spread. As Johnson & Johnson begins shipping its Janssen COVID-19 Vaccine this week in the U.S., after …
Ontario Together Fund continues to support homegrown manufacturing and innovation to provide goods critical to the health, safety, and security of the people of Ontario GUELPH — The Ontario government is supporting an investment of nearly $15 million by Johnson & Johnson Inc., makers of over-the-counter pharmaceuticals for adults and children. The province is investing $2.5 million through the Ontario …
